MET-specific inhibitors, such as Tepotinib and Capmatinib, have been FDA-approved for the treatment of metastatic non-small cell lung cancer (NSCLC) with MET exon 14 skipping activation mutations. The gene discussed is MET; the disease is non-small cell lung carcinoma.